TABLE 1.
In vitro activities of CEM-101 and other antimicrobials against Mycoplasma and Ureaplasma species isolated from humans
| Organism (no. of isolates) and antimicrobial | MIC range (μg/ml) | MIC50 (μg/ml)a | MIC90 (μg/ml)a |
|---|---|---|---|
| M. pneumoniae (36) | |||
| CEM-101 | ≤0.000000063-0.5 | 0.000032 | 0.000125 |
| Azithromycin | ≤0.000016 to ≥32 | 0.00025 | 0.0005 |
| Telithromycin | 0.000031 to ≥32 | 0.00025 | 0.001 |
| Doxycycline | 0.016-0.25 | 0.125 | 0.25 |
| Levofloxacin | 0.125-1 | 0.5 | 0.5 |
| Linezolid | 32-128 | 64 | 128 |
| M. genitalium (5) | |||
| CEM-101 | ≤0.000032 | NA | NA |
| Azithromycin | ≤0.000032-0.005 | NA | NA |
| Telithromycin | ≤0.00003-0.00025 | NA | NA |
| Doxycycline | ≤0.008-0.031 | NA | NA |
| Levofloxacin | 0.125-1 | NA | NA |
| Linezolid | 4-128 | NA | NA |
| M. fermentans (15) | |||
| CEM-101 | ≤0.008 | ≤0.008 | ≤0.008 |
| Azithromycin | 0.125-1 | 0.5 | 0.5 |
| Telithromycin | 0.002-0.031 | ≤0.008 | 0.016 |
| Clindamycin | ≤0.008-0.063 | 0.016 | 0.031 |
| Doxycycline | 0.016-0.5 | 0.125 | 0.5 |
| Levofloxacin | ≤0.008-0.25 | 0.031 | 0.125 |
| Linezolid | 0.5-4 | 1 | 4 |
| M. hominis (13) | |||
| CEM-101 | 0.002-0.008 | 0.004 | 0.008 |
| Azithromycin | 0.5-4 | 4 | 2 |
| Telithromycin | 0.125-0.5 | 0.25 | 0.5 |
| Clindamycin | ≤0.008-0.031 | ≤0.008 | 0.016 |
| Doxycycline | ≤0.008-0.016 | 0.125 | 8 |
| Levofloxacin | 0.125-0.5 | 0.25 | 0.5 |
| Linezolid | 1-8 | 2 | 4 |
| U. parvum (10) | |||
| CEM-101 | 0.002-0.031 | 0.008 | 0.016 |
| Azithromycin | 0.5-4 | 2 | 4 |
| Telithromycin | 0.008-0.063 | 0.063 | 0.125 |
| Doxycycline | 0.031-16 | 8 | 16 |
| Levofloxacin | 0.125-2 | 0.5 | 2 |
| Linezolid | 128 to >256 | >256 | >256 |
| U. urealyticum (10) | |||
| CEM-101 | 0.004-0.063 | 0.008 | 0.031 |
| Azithromycin | 0.5-4 | 2 | 4 |
| Telithromycin | 0.016-0.25 | 0.063 | 0.25 |
| Doxycycline | 0.031-32 | 1 | 16 |
| Levofloxacin | 0.5-2 | 0.5 | 1 |
| Linezolid | 256 to >256 | >256 | >256 |
NA, not applicable.